Welcome to our dedicated page for Caredx news (Ticker: CDNA), a resource for investors and traders seeking the latest updates and insights on Caredx stock.
CareDx Inc (CDNA) delivers innovative non-invasive diagnostics for transplant patient care through advanced genomics and bioinformatics. This news hub provides investors and healthcare professionals with essential updates on the company's developments in precision medicine.
Key resources include: Earnings reports detailing financial performance in transplant diagnostics, regulatory updates on FDA-cleared testing solutions, and strategic partnership announcements expanding into hematology oncology. Track clinical trial outcomes validating AlloSure® monitoring and discover operational milestones in digital health integration.
Our curated collection enables efficient tracking of CDNA's progress in reducing invasive biopsies through blood-based dd-cfDNA analysis. Stay informed about innovations in kidney, heart, and lung transplant surveillance technologies that are reshaping organ rejection management.
Bookmark this page for real-time updates on CareDx's evidence-based diagnostic solutions and their impact on transplant care standards. Verify analysis dates and consult official filings for complete context on all developments.
CareDx, Inc. (Nasdaq: CDNA) showcased its AlloSure surveillance tool during the virtual ASN annual conference from October 22-25, 2020, reflecting increasing interest from nephrologists.
Eleven abstracts highlighting AlloSure were presented, underscoring its significance in transplant patient management. The company also sponsored an educational symposium titled Diagnostic Controversies in Transplantation. Notably, real-world data from over 1,000 patients will be shared, showing positive clinical outcomes associated with the AlloSure tool.
CareDx announces that the Centers for Medicare and Medicaid Services (CMS) has recommended continued coverage of AlloMap for heart transplant patients via local Medicare Administrative Contractors (MACs). This follows a memo acknowledging multiple studies demonstrating AlloMap's clinical utility since its initial request for a national coverage determination in 2013. AlloMap, adopted by over 90% of U.S. transplant centers and supported by ISHLT guidelines, continues to receive reimbursement, affirming its status as the standard of care in transplant medicine.
CareDx, Inc. (CDNA) announced its participation in the virtual 46th annual ASHI conference, taking place from October 19-21, 2020. The company will showcase its latest innovations for HLA laboratories, including a symposium led by Dr. Rajalingam Raja on October 20, highlighting the AlloSeq Tx17 HLA typing solution. Presentations and posters will cover various advancements in HLA typing, including hybrid capture techniques and genetic risk factors in transplantation. CareDx aims to strengthen community engagement and share updates on best practices in transplant patient care.
CareDx, Inc. (Nasdaq: CDNA) will release its third-quarter 2020 financial results on October 29, 2020, after market close. The conference call to review these results will be hosted by CEO Peter Maag and CFO Michael Bell at 1:30 PM PT. Interested parties can join the call by dialing 877-705-6003 or via webcast on CareDx's investor relations page. A replay will be available from October 29 at 4:30 PM PT until November 12, 2020. CareDx specializes in precision medicine for transplant patients.
CareDx, Inc. (CDNA) announced a preliminary revenue of approximately $53.0 million for Q3 2020, a 57% increase from $33.8 million in Q3 2019. This growth was driven by testing revenue of $45.2 million, up from $28.2 million year-over-year. Notably, around 21,800 AlloSure and AlloMap tests were conducted during the quarter. The company emphasizes its commitment to supporting transplant patients amid the pandemic and continues to invest in growth and digital solutions for enhanced patient care.
CareDx, Inc. (Nasdaq: CDNA) announced pivotal clinical data publications for AlloSure Lung, a non-invasive biomarker for acute cellular rejection (ACR) in lung transplant patients. The LARGO study, involving 69 patients, demonstrated AlloSure's effectiveness in identifying ACR without invasive procedures. Additionally, the University of Texas San Antonio published findings from a cohort of 48 patients, emphasizing the tool's value for monitoring allograft dysfunction, especially during the COVID-19 pandemic. Experts highlight AlloSure Lung as a promising advancement in transplant care.
CareDx, Inc. (Nasdaq: CDNA) announced the release of a final local coverage determination by Palmetto MolDx for AlloSure Heart, a dd-cfDNA test identifying cell injury that leads to organ rejection. Medicare reimbursement for this test follows a thorough technical assessment, highlighting its clinical utility in transplant management. This decision facilitates the launch of HeartCare, which combines AlloSure Heart with AlloMap Heart, offering a comprehensive, non-invasive solution for heart transplant patients during the COVID pandemic. This coverage enhances patient access and optimizes care management.
CareDx, Inc. (Nasdaq: CDNA) launched AlloCare, a mobile app aimed at enhancing medication adherence and health management for transplant patients. The app will debut at the AlloCare Transplant Festival on September 26, 2020, designed to foster connections within the transplant community. The festival will feature notable personalities and over 25 transplant organizations, emphasizing CareDx's commitment to improving long-term outcomes through innovative patient engagement solutions. The app is now available for download in the Apple App Store.
CareDx, Inc. (CDNA) announced its participation in the 28th International Congress of The Transplantation Society (TTS) from September 13-16, 2020. The company will showcase its AlloSure and AlloSeq cfDNA tools through four virtual symposia and six poster presentations. Expert speakers will discuss topics like risk prediction in kidney transplantation and the use of dd-cfDNA as a biomarker. CareDx aims to support continuous education for the transplant community and emphasize innovations in transplant medicine.
CareDx, Inc. (NASDAQ: CDNA), a precision medicine leader, has appointed new senior executives in key areas: Digital Services, Laboratory Operations, Business Development, and Market Access. The appointments aim to enhance operational efficiency amidst rapid growth. Notable new hires include Kashif Rathore, Ryan Phan, Sean Grant, and Danielle Scelfo, each bringing extensive experience from leading companies. CEO Peter Maag emphasizes the need for robust leadership to navigate increasing operational complexities and advance CareDx's market strategies.
